Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series B | Alive

Total Raised


Last Raised

$76M | 3 yrs ago

About Blackthorn Therapeutics

BlackThorn Therapeutics is a clinical-stage neurobehavioral health company developing artificial intelligence technologies to advance its pipeline of targeted therapeutics for treating brain disorders. The company has engineered PathFinder, a cloud-based computational psychiatry and data platform, to enable the collection, integration and analysis of multimodal data at great speed and scale. BlackThorn applies its data-driven approaches to create an understanding of the core underlying pathophysiology of neurobehavioral disorders and uses these insights to generate objective neuromarkers, which support drug target identification, patient stratification and objective clinical trial endpoints. By identifying more homogenous patient subgroups who share underlying neurobiology, BlackThorn aims to direct its drug candidates to neurobiologically-defined patient populations most likely to respond.

Blackthorn Therapeutics Headquarters Location

780 Brannan Street

San Francisco, California, 94103,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Blackthorn Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Blackthorn Therapeutics in 2 CB Insights research briefs, most recently on Feb 16, 2022.

Expert Collections containing Blackthorn Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Blackthorn Therapeutics is included in 3 Expert Collections, including Digital Health.


Digital Health

21,952 items

Startups recreating how healthcare is delivered


Artificial Intelligence

9,391 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Biopharma Tech

6,079 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Blackthorn Therapeutics Patents

Blackthorn Therapeutics has filed 20 patents.

The 3 most popular patent topics include:

  • Psychiatric diagnosis
  • Machine learning
  • Classification algorithms
patents chart

Application Date

Grant Date


Related Topics




Psychiatric diagnosis, Machine learning, Clinical psychology tests, Abnormal psychology, Classification algorithms


Application Date


Grant Date



Related Topics

Psychiatric diagnosis, Machine learning, Clinical psychology tests, Abnormal psychology, Classification algorithms



Latest Blackthorn Therapeutics News

Severity of PTSD symptoms linked to decreased activity in hippocampus

Jul 25, 2022

Credit: Tanriverdi et al., JNeurosci 2022 After a traumatic event, people with decreased activity in the hippocampus experience worse PTSD symptoms, according to new research published in JNeurosci. The hippocampus does more than encode new memories — it also takes stock of spatial and emotional contexts and processes threat. PTSD impacts all of these functions, generating symptoms like the overgeneralization of fear and recurrent traumatic memories. Yet the exact interplay between the hippocampal activity and PTSD was unclear. Tanriverdi et al. measured PTSD symptoms and hippocampal activity in people who had visited the emergency room after a traumatic event like a car crash. Participants answered a questionnaire about PTSD symptoms, then they viewed frightened and neutral faces while the researchers measured their brain activity with fMRI. People with more severe PTSD symptoms had decreased activity in the hippocampus in response to the frightened faces. This relationship strengthened in people who startled more easily in a defensive learning task. For these participants, their hippocampus may not be discriminating between safe and unsafe contexts. These results indicate certain individuals may be more susceptible to PTSD because of impaired activity in their hippocampus. ### Paper title: Hippocampal Threat Reactivity Interacts with Physiological Arousal to Predict PTSD Symptoms Please contact  [email protected]  for the full-text PDF and to join SfN’s journals media list. About JNeurosci JNeurosci, the Society for Neuroscience’s first journal, was launched in 1981 as a means to communicate the findings of the highest quality neuroscience research to the growing field. Today, the journal remains committed to publishing cutting-edge neuroscience that will have an immediate and lasting scientific impact, while responding to authors’ changing publishing needs, representing breadth of the field and diversity in authorship. About The Society for Neuroscience The Society for Neuroscience is the world’s largest organization of scientists and physicians devoted to understanding the brain and nervous system. The nonprofit organization, founded in 1969, now has nearly 37,000 members in more than 90 countries and over 130 chapters worldwide. Journal Article Publication Date COI Statement Dr. Ressler has served on advisory boards for Takeda, Resilience Therapeutics, Janssen and Verily/Google. His research has been sponsored by Alkermes and Brainsway and he has worked as a consultant for Alkermes. In the last three years, Dr. Clifford has received research funding from the NSF, NIH and LifeBell AI, and unrestricted donations from AliveCor, Amazon Research, the Center for Discovery, the Gordon and Betty Moore Foundation, MathWorks, Microsoft Research, the Gates Foundation, Google, One Mind Foundation, and Samsung Research. Dr. Clifford has financial interest in AliveCor and receives unrestricted funding from the company. He also is the CTO of MindChild Medical and CSO of LifeBell AI and has ownership in both companies. These relationships are unconnected to the current work. Dr. Germine is on the scientific advisory board of the nonprofit Sage Bionetworks, for which she receives a small honorarium. Dr. Sheikh has received funding from the Florida Medical Malpractice Joint Underwriter’s Association Dr. Alvin E. Smith Safety of Healthcare Services Grant, Allergan Foundation, the NIH/NIA-funded Jacksonville Aging Studies Center (JAX-ASCENT; R33AG05654), the Substance Abuse and Mental Health Services Administration (1H79TI083101-01), and the Florida Blue Foundation. Dr. Jones reports no direct conflicts related to this paper, and no ongoing conflicts. He has been an investigator on studies funded by Hologic Inc, Janssen, and AstraZeneca, for which his department has received research funding. Over the past 3 years, Dr. Pizzagalli has received consulting fees from BlackThorn Therapeutics, Boehringer Ingelheim, Compass Pathway, Concert Pharmaceuticals, Engrail Therapeutics, Neurocrine Biosciences, Otsuka Pharmaceuticals, and Takeda Pharmaceuticals; one honorarium from Alkermes, and research funding from Millennium Pharmaceuticals. In addition, he has received stock options from BlackThorn Therapeutics. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. Dr. Elliott reports support from the National Institutes of Health (NIH) through Grant Numbers R01HD079076 & R03HD094577, Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Center for Medical Rehabilitation Research, and South Wales Health Spinal Cord Injury Research Grants Program. In the past 3 years, Dr. Kessler was a consultant for Datastat, Inc., RallyPoint Networks, Inc., Sage Pharmaceuticals, and Takeda. The remaining authors report no financial relationships with commercial interests.

Blackthorn Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Blackthorn Therapeutics Rank

  • When was Blackthorn Therapeutics founded?

    Blackthorn Therapeutics was founded in 2016.

  • Where is Blackthorn Therapeutics's headquarters?

    Blackthorn Therapeutics's headquarters is located at 780 Brannan Street, San Francisco.

  • What is Blackthorn Therapeutics's latest funding round?

    Blackthorn Therapeutics's latest funding round is Series B.

  • How much did Blackthorn Therapeutics raise?

    Blackthorn Therapeutics raised a total of $130M.

  • Who are the investors of Blackthorn Therapeutics?

    Investors of Blackthorn Therapeutics include ARCH Venture Partners, Google Ventures, Mercury Fund, Scripps Research Institute, Altitude Life Science Ventures and 10 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.